lasmiditan
Trade name: Reyvow
Small moleculeapproved
Approved
Oct 11, 2019
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine. — NCATS
Clinical trial activity
33 trials · 8 clinical orgs · 3 marketing orgs
Phase 1
21
Phase 2
12
Phase 3
8
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00384774)
Timeline
2010s
2020s
- Dec 20, 2024
Qilu Pharmaceutical Co., Ltd. — Marketing Organization
- Dec 19, 2025
Yichang Humanwell Pharmaceutical Co.,Ltd — Marketing Organization
Indications
Approved for
Mechanism of action
HTR1F agonist
Approval history
- approvedOct 11, 2019
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2- Mol. weight
- 377.3603 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
First in class
Sources
- WikipediaLasmiditan ↗
- NCATS760I9WM792 ↗
- ChEMBLCHEMBL3039526 ↗
- ChEMBLCHEMBL3039520 ↗
Also known as
- 2,4,6-trifluoro-n-(6-((1-methylpiperidin-4-yl)carbonyl)pyridin-2yl)benzamide
- col-144
- col-144
- col-144
- las106521
- lasmiditan
- lasmiditan
- lasmiditan
- lasmiditan
- lasmiditan hydrochloride
- ly573144
- ly573144
- ly-573144
- ly-573144
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04881747 | Phase 1 | May 14, 2021 | Eli Lilly |
| NCT04749914 | Phase 1 | Feb 15, 2021 | Eli Lilly |
| NCT04396574 | Phase 3 | Jun 15, 2020 | Eli Lilly |
| NCT04396236 | Phase 3 | Jun 15, 2020 | Eli Lilly |
| NCT04218162 | Phase 3 | Mar 1, 2020 | IlDong Pharmaceutical Co Ltd |
| NCT04081324 | Phase 1 | Nov 18, 2019 | Eli Lilly |
| NCT03937648 | Phase 1 | Aug 1, 2019 | IlDong Pharmaceutical Co Ltd |
| NCT03988088 | Phase 1 | Jun 28, 2019 | Eli Lilly |
| NCT03962738 | Phase 2 | May 31, 2019 | Eli Lilly |
| NCT03670810 | Phase 3 | Nov 20, 2018 | Eli Lilly |
| NCT03579940 | Phase 1 | Jun 27, 2018 | Eli Lilly |
| NCT03459612 | Phase 1 | Mar 26, 2018 | Eli Lilly |
| NCT03406260 | Phase 1 | Jan 25, 2018 | Eli Lilly |
| NCT03310411 | Phase 1 | Oct 17, 2017 | Eli Lilly |
| NCT03308669 | Phase 1 | Oct 16, 2017 | Eli Lilly |
| NCT03286218 | Phase 1 | Sep 15, 2017 | Eli Lilly |
| NCT03270644 | Phase 1 | Aug 31, 2017 | Eli Lilly |
| NCT03247790 | Phase 1 | Aug 16, 2017 | Eli Lilly |
| NCT03252015 | Phase 1 | Aug 15, 2017 | Eli Lilly |
| NCT03182920 | Phase 1 | Jun 16, 2017 | Eli Lilly |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 19 | 19 | 3 | 2011 |
| CoLucid Pharmaceuticals | For profit | 11 | 10 | 3 | 2006 |
| Sponsor GmbH | Academic/Hospital | 4 | 0 | 2 | 2015 |
| Algorithme Pharma Inc | For profit | 2 | 0 | 1 | 2017 |
| Almirall | For profit | 2 | 2 | 2 | 2008 |
| IlDong Pharmaceutical Co Ltd | For profit | 2 | 2 | 2 | 2019 |
| Cognitive Research Corporation | For profit | 1 | 0 | 1 | 2017 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2009 |
8 organizations
Page 1 / 1
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | MKTG | Oct 11, 2019 |
| Eli Lilly | For profit | NDA | Oct 11, 2019 |
| Qilu Pharmaceutical Co., Ltd. | For profit | MKTG | Dec 20, 2024 |
| Yichang Humanwell Pharmaceutical Co.,Ltd | For profit | MKTG | Dec 19, 2025 |